Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

DISEASE CHARACTERISTICS:

Histologically confirmed lymphoproliferative disease

CD20-positive disease
Bidimensionally measurable disease OR abnormal cells detected in blood

Resistant or refractory to standard therapies and/or unlikely to benefit from additional standard therapies* AND meets 1 of the following criteria:

Disease with anticipated response rate < 20% after treatment with rituximab alone, including any of the following:

Diffuse large cell lymphoma
B-cell lymphoblastic lymphoma
Burkitt's lymphoma
Acute lymphocytic leukemia

Relapsed or progressive disease after prior treatment with rituximab, including any of the following:

Hodgkin's lymphoma
Hairy cell leukemia

Chronic lymphocytic leukemia/small lymphocytic lymphoma meeting any of the following criteria:

Received prior fludarabine phosphate-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies
Received prior anti-CD52 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy)
Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment

B-cell prolymphocytic leukemia meeting any of the following criteria:

Received prior fludarabine phosphate- or alkylating agent-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies
Received prior anti-CD52 monoclonal antibody therapy OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy)

Lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, or follicular lymphoma meeting any of the following criteria:

Received prior fludarabine phosphate- and/or alkylating agent-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies
Received prior anti-CD20 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy
Received prior radioconjugated anti-CD20 monoclonal antibody therapy OR ineligible to receive such therapy
Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment

Multiple myeloma meeting any of the following criteria:

Received prior alkylating agent-, thalidomide-, corticosteroid-, or bortezomib-containing regimens and relapsed after 1 year of treatment OR ineligible to receive such therapies due to comorbidities or allergies
Received prior high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR ineligible to receive such therapy

Mantle cell lymphoma meeting the following criteria:

Received prior combination chemotherapy and anti-CD20 monoclonal antibody therapy and relapsed after treatment OR ineligible to receive such therapy

Diffuse large B-cell lymphoma meeting any of the following criteria:

Received prior combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy
Received prior salvage combination chemotherapy with or without high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR not a candidate to receive such therapy
Received prior radiolabeled anti-CD20 monoclonal antibody therapy for transformed large cell lymphoma OR ineligible to receive such therapy

Burkitt's lymphoma meeting any of the following criteria:

Received prior combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy
Received prior salvage combination chemotherapy with or without high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR ineligible to receive such therapy

Lymphomatoid granulomatosis meeting any of the following criteria:

Received prior single-agent or combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy
Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment

Acute lymphocytic leukemia meeting any of the following criteria:

Received prior multi-agent combination chemotherapy administered in sequential induction, consolidation, and maintenance courses and relapsed during or after treatment OR ineligible to receive such therapy
Received prior chemotherapy with or without radiotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) and relapsed after treatment OR not a candidate for such therapy
Received prior treatment with chemotherapy with or without radiotherapy followed by allogeneic HSCT and relapsed after treatment (or not a candidate for such therapy) AND demonstrates persistent cytogenetic, fluorescent in situ hybridization, or molecular (reverse transcriptase-polymerase chain reaction) evidence of the bcr-abl fusion gene despite 6 weeks of treatment with imatinib mesylate NOTE: *Not eligible to receive standard available salvage regimens anticipated to result in durable remission
No active CNS malignancy
Not considered a candidate for allogeneic HSCT
HLA-partially matched (≥ 2/6) related donor available

PATIENT CHARACTERISTICS:

ECOG performance status 0-1
Life expectancy > 3 months
Not pregnant
Negative pregnancy test
Fertile women must use effective contraception
Bilirubin < 1.5 times upper limit of normal (ULN)
AST < 3.0 times ULN
Cardiac ejection fraction > 35%
Absolute neutrophil count > 1,000/mm³ (without cytokines)
Platelet count > 50,000/mm³ (untransfused)
No significant organ dysfunction
No active uncontrolled infections
No hypersensitivity reaction to rituximab that has precluded completion of a 4-week course of rituximab therapy
No uncontrolled psychiatric illness or medical condition that would preclude tolerance of study treatment

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Recovered from prior therapy for at least 7 days
More than 30 days since prior cytotoxic chemotherapy
At least 14 days since prior steroids
At least 14 days since prior radiotherapy to non-target lesions